We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EVLV:NASDAQEvolv Technologies Holdings, Inc. Analysis

Data as of 2026-04-01 - not real-time

$6.02

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Evolv Technologies posted a surprising earnings beat, delivering $0.06 per share versus the consensus loss of $0.08, and outpacing revenue estimates by roughly 5%, underscoring a robust top‑line momentum with 32% year‑over‑year revenue growth and a healthy operating margin of 22%. The company also generated positive operating cash flow of $18.7 M and modest free cash flow, while maintaining a solid cash cushion of $69 M against $42 M of debt, suggesting short‑term financial stability. Technical indicators are mixed: the stock trades above its 20‑day (≈$5.53) and 50‑day (≈$5.62) moving averages, the MACD histogram remains bullish, and the RSI sits at a neutral 59, yet the price remains below the 200‑day average (≈$6.72) and the broader trend is still classified as bearish. Volume has been decreasing, and volatility is elevated at over 64% annualized, highlighting heightened price swings.
Valuation remains a key concern: the DCF‑derived fair value of roughly $0.52 is far below the current market price of $6.02, and the price‑to‑book ratio of 8.8 signals significant overvaluation relative to book assets. While the sector’s security‑technology niche offers growth potential, the lack of profitability (negative profit margin and EPS) and a high beta of 1.11 amplify market risk. Investors should weigh the short‑term upside from the earnings momentum against the long‑term valuation disconnect and elevated volatility.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Recent earnings surprise and revenue beat
  • Bullish MACD and price above short‑term SMAs
  • Positive operating cash flow supporting near‑term liquidity

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Overvaluation relative to DCF fair value
  • Sustained revenue growth but ongoing net losses
  • Elevated volatility and decreasing volume

Long Term

> 3 years
Cautious
Model confidence: 4/10

Key Factors

  • Significant valuation gap (price vs intrinsic value)
  • Negative profitability metrics (profit margin, EPS)
  • High beta and bearish long‑term trend

Key Metrics & Analysis

Financial Health

Revenue Growth32.30%
Profit Margin-22.71%
P/E Ratio-225.5
ROE-27.96%
ROA-6.38%
Debt/Equity35.37
P/B Ratio8.8
Op. Cash Flow$18.7M
Free Cash Flow$1.8M
Industry P/E29.1

Technical Analysis

TrendBearish
RSI59.2
Support$4.88
Resistance$6.22
MA 20$5.53
MA 50$5.62
MA 200$6.72
MACDBullish
VolumeDecreasing
Fear & Greed Index77.91

Valuation

Fair Value$0.52
Target Price$10.00
Upside/Downside66.25%
GradeOvervalued
TypeBlend

Risk Assessment

Beta1.11
Volatility64.40%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.